-
Mashup Score: 2Unraveling the Natural History of Good’s Syndrome: A Progressive Adult Combined Immunodeficiency - 2 month(s) ago
Good’s syndrome (GS) is a rare immune deficiency described almost 6 decades ago. Despite numerous published individual case reports and data collected in cross-sectional studies of small cohorts, the natural history and long-term outcomes of this disease remain unknown.
Source: www.jaci-inpractice.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 0Chronic or recurrent Campylobacter enteritis in primary immunodeficiency: A UK national case-series and review of the literature - 7 month(s) ago
Campylobacter infection, usually by Campylobacter jejuni, is the most common cause of bacterial enteritis in the world. In healthy individuals, the infection is self-limiting, but in patients with immunodeficiency, recurrent or persistent symptomatic infection may occur. In this case series, we present a cohort of primary immunodeficiency patients with chronic or recurrent Campylobacter enteritis from the United Kingdom and review the previously published literature.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 8Combined immunodeficiency with autoimmunity caused by a homozygous missense mutation in inhibitor of nuclear factor 𝛋B kinase alpha (IKKα) - 9 month(s) ago
A mutation in human IKKα compromises noncanonical NF-κB signaling resulting in primary immunodeficiency associated with autoimmunity.
Source: www.science.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
Campylobacter infection usually causes a self-limited clinical illness lasting 5 to 7 days, resolving without antimicrobial treatment in immunocompetent subjects. However, an inadequate immune response can lead to a prolonged and severe disease requiring antibiotics and more aggressive therapeutic approaches.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Expanded Indication for Hyqvia to Treat Pediatric Primary Immunodeficiency - 1 year(s) ago
During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.
Source: Pharmacy TimesCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0The rapidly expanding genetic spectrum of Common Variable Immunodeficiency-like disorders - 1 year(s) ago
The understanding of Common Variable Immunodeficiency Disorders (CVID) is in evolution. CVID was previously a diagnosis of exclusion. New diagnostic criteria have allowed the disorder to be identified with greater precision. With the advent of Next Generation Sequencing (NGS), it has become apparent that an increasing number of patients with a CVID phenotype have a causative genetic variant. If a…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1Early Diagnosis of Primary Immunodeficiency Disease Using Clinical Data and Machine Learning - 2 year(s) ago
Primary immunodeficiency diseases (PIDD) are a group of immune-related disorders that have a current median delay of diagnosis between 6 and 9 years. Early diagnosis and treatment of PIDD has been associated with improved patient outcomes.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Lessons Learned From Five Years of Newborn Screening for Severe Combined Immunodeficiency in Israel - 2 year(s) ago
Implementation of newborn screening (NBS) programs for severe combined immunodeficiency (SCID) have advanced the diagnosis and management of affected infants and undoubtedly improved their outcomes. Reporting long-term follow-up of such programs is of great importance.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1Early Diagnosis of Primary Immunodeficiency Disease Using Clinical Data and Machine Learning - 2 year(s) ago
Primary immunodeficiency diseases (PIDD) are a group of immune-related disorders that have a current median delay of diagnosis between six and nine years. Early diagnosis and treatment of PIDD has been associated with improved patient outcomes.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry - 2 year(s) ago
Optimal management of patients with combined immunodeficiency, especially pertaining to hematopoietic stem cell transplantation (HSCT), remains unclear.
Categories: Allergy-Immunology, Latest HeadlinesTweet
In Current Issue! Unraveling the Natural History of Good’s Syndrome: A Progressive Adult Combined #Immunodeficiency https://t.co/fuVgMWtJtQ https://t.co/7VZdIeosv8